Q-omics provides the consensus-scored RAB22A profile across patient tissues and cancer cell-line models. RAB22A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RAB22A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RAB22A RNA expression shows 21,231 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where RAB22A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB22A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB22A survival associations across molecular data types. RAB22A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB22A RNA expression–survival associations across cancer types. High RAB22A expression shows unfavorable associations in BLCA, UVM, LIHC, KICH, KIRP and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RAB22A RNA expression.
This table summarizes RAB22A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB22A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB22A shows higher tumor expression in HNSC, STAD, LUAD, LIHC, COAD and KIRP. The HNSC box plot shows higher RAB22A RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with RAB22A in patient tissues and cancer cell lines. In patient samples, RAB22A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB22A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
